One of the most widely used methods for detecting, diagnosing, and treating cancer, particularly lung and colorectal tumours, is the computed tomography, or CT, scan.
Imaging has emerged as a crucial tool for the research of cancer biology as well as for clinical diagnosis and care. New molecular probes of cell kinds and metabolic states, along with rapid advancements in high resolution fluorescence imaging at the single cell level and MR/PET/CT image registration, will make it possible to bridge the physical scales that each modality images.
The Global Tumor imaging system market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
Pre-clinical research can take use of the potential of MRI with the M-SeriesTM Compact MRI systems without the expense, complexity, and technical burden of traditional systems. The most effective method for detecting tumours in soft tissues during a longitudinal investigation is MRI.
A miniaturised fluorescent endo microscope device called the FIVE2 (ViewnVivo) enables preclinical researchers to capture confocal images with unmatched resolution and image quality.
Over the course of a longitudinal investigation, molecular and microvascular events may be noticed.
An revolutionary optical bioluminescence and fluorescence imaging device created with the user in mind is called the Newton 7.0.
It allows for the simultaneous imaging of numerous animals or samples at once, making it perfect for in vivo, ex vivo, and in vitro imaging applications.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.